| Citation: |
Caidong Hu, Xiaofeng Luo, Na Xian, Chenjing Ye, Guolin Hu, Jinhua Ren, Xiaoyun Zheng, Jing Li, Xiaozhu Yang, Hao Zheng, Yongzhi Zheng, Zhongchao Han, Gangxiong Huang, Jianda Hu, Ting Yang. Induction of Cytokine Storm with Organ Dysfunction and Ineffective Response to Tocilizumab and Steroids by CAR-T Cell Therapy is Rescued by Mesenchymal Stem Cells: A Case Report[J]. Blood&Genomics, 2024, 8(1): 10006. DOI: 10.70322/BG20240110006
|
Two of the main toxicities linked with chimeric antigen receptor T (CAR-T) cell therapy are cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). It is believed that an inflammatory factor storm resulting in organ dysfunction is the fundamental pathophysiology, and this has a significant impact on the survival rate following CAR-T cell therapy. While steroids and other IL-6R antagonists like Tocilizumab are useful treatment approaches, not all patients benefit from them. Following CD19-targeted CAR-T cell infusion, a 3-year-old kid with relapsed refractory B-cell acute lymphoblastic leukemia (ALL) started to have CRS on Day 1. Despite receiving steroids and tocilizumab early on, his illness worsened and eventually led to multiple organ failure, particularly heart failure. After receiving mesenchymal stem cells (MSCs) as a rescue treatment on Days 17 and 20, the patient's clinical symptoms were stabilized by Day 25. Negative microscopic residual disease (MRD) was achieved with CAR-T therapy, and CAR expression was maintained in peripheral blood until Day 75. The case implies that MSC may be a useful treatment for multi-organ dysfunction that results from severe CRS and ICANS brought on by CAR-T cell therapy.
| [1] |
. Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci. Immunol. 2020, 5, eaax7969.
|
| [2] |
. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 2018, 24, 739–748.
|
| [3] |
. Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J. Exp. Clin. Cancer Res. 2021, 40, 367.
|
| [4] |
. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016, 127, 3321–3330.
|
| [5] |
. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 2018, 32, 1091–1101.
|
| [6] |
. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 2019, 133, 2212–2221.
|
| [7] |
. Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr. Opin. Immunol. 2015, 34, 75–82.
|
| [8] |
. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 2019, 16, 45–63.
|
| [9] |
. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song G. Mesenchymal stem cell migration and tissue repair. Cells 2019, 8, 784.
|
| [10] |
. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 2018, 24, 731–738.
|
| [11] |
. Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J. Immunother. Cancer 2022, 10, e003766.
|
| [12] |
. Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 2019, 25, 1408–1414.
|
| [13] |
. Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 2020, 183, 126–142.
|
| [14] |
. Zhu H, Lan L, Zhang Y, Chen Q, Zeng Y, Luo X, et al. Epidermal growth factor stimulates exosomal microRNA-21 derived from mesenchymal stem cells to ameliorate aGVHD by modulating regulatory T cells. FASEB J. 2020, 34, 7372–7386.
|
| [15] |
. Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp. Hematol. Oncol. 2020, 9, 15.
|
| [16] |
. Chen Q, Zhang Y, Zhu H, Yuan X, Luo X, Wu X, et al. Bone marrow mesenchymal stem cells alleviate the daunorubicin-induced subacute myocardial injury in rats through inhibiting infiltration of T lymphocytes and antigen-presenting cells. Biomed Pharmacother. 2023, 164, 114940.
|
| [17] |
. Zhu R, Yan T, Feng Y, Liu Y, Cao H, Peng G, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021, 31, 1244–1262.
|
| [18] |
. Zanetti SR, Romecin PA, Vinyoles M, Juan M, Fuster JL, Cámos M, et al. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. J. Immunother. Cancer 2020, 8, e001419.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: